General Information
|
|
Product
|
TLR3 Peptide
|
Description
|
Antigenic Blocking Peptide Toll-like receptor 3
|
Verified Applications
|
Immunocompeition, Immunodepletion
|
Peptide Description
|
Synthetic peptide taken within amino acid region 650-700 on human TLR3 protein.
|
Accession #
|
GenBank: AAH96333.1
|
Physical Properties
|
|
Quantity
|
250 µg
|
Volume
|
100 µl
|
Form
|
Antigenic Blocking Peptide
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
Protein
|
Uniprot #
|
O15455
|
Overview
|
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection.
|
Molecular Function
|
Receptor, double-stranded RNA binding, transmembrane signaling receptor activity
|
Subcellular Location
|
Endoplasmic reticulum membrane; Single-pass type I membrane protein, Endosome membrane
|
Expression
|
Expressed at high level in placenta and pancreas. Also detected in CD11c+ immature dendritic cells. Only expressed in dendritic cells and not in other leukocytes, including monocyte precursors. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons.
|
Structure
|
Monomer and homodimer; dimerization is triggered by ligand-binding, the signaling unit is composed of one ds-RNA of around 40 bp and two TLR3 molecules, and lateral clustering of signaling units along the length of the ds-RNA ligand is required for TLR3 signal transduction. Interacts (via transmembrane domain) with UNC93B1; the interaction is required for transport from the ER to the endosomes.
|
Alternative Nomenclature
|
CD283 antibody
CD283 antigen antibody
IIAE2 antibody
TLR 3 antibody
Toll Like Receptor 3 antibody
|
|
|